Wave Life Sciences (WVE) FCF Margin (2015 - 2026)
Wave Life Sciences' (WVE) quarterly FCF Margin came in at 2397.27% in Q2 2026, down 186482.0% YoY from N/an in Q2 2025, and down 1428.33% on a QoQ basis from 156.86% in Q1 2026.
Powered by 
Analysis
Wave Life Sciences (WVE) FCF Margin (2015 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 12 years of FCF Margin data on file, last reported at 2397.27% in Q2 2026.
- Quarterly FCF Margin fell 186482.0% year-over-year to 2397.27% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 330.77% (up 6863.0% YoY) and the FY2025 annual result came in at 440.5%, down 30018.0% from the prior year.
- FCF Margin eased to 2397.27% in Q2 2026, from 156.86% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 657.69% in Q1 2023 to a low of 9158.95% in Q3 2022.
- A 5-year average of 1847.44% and a median of 401.21% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin sank 908130 bps — and 2023, when it surged 908853 bps.
- Tracing WVE's FCF Margin over 5 years: stood at 2715.42% in 2022, then soared by 96 bps to 115.62% in 2023, then retreated by 21 bps to 139.75% in 2024, then plunged by 281 bps to 532.45% in 2025, then plunged by 350 bps to 2397.27% in 2026.
- The last three FCF Margin figures came in at 2397.27% (Q2 2026), 156.86% (Q1 2026), and 532.45% (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Wave Life Sciences | 994.54 Mn | 626.53 Mn | - | -2,397.27% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,397.27% |
| Mar 31, 2026 | -156.86% |
| Dec 31, 2025 | -195.85% |
| Sep 30, 2025 | -590.35% |
| Jun 30, 2025 | -532.45% |
| Mar 31, 2025 | -688.87% |
| Dec 31, 2024 | -52.22% |
| Sep 30, 2024 | -610.49% |
| Jun 30, 2024 | -139.75% |
| Mar 31, 2024 | -269.97% |
| Dec 31, 2023 | -115.62% |
| Sep 30, 2023 | -70.42% |
| Jun 30, 2023 | -168.86% |
| Mar 31, 2023 | 657.69% |
| Dec 31, 2022 | -2,715.42% |
| Sep 30, 2022 | -9,158.95% |
| Jun 30, 2022 | -7,817.07% |
| Mar 31, 2022 | -2,290.34% |
| Dec 31, 2021 | -399.32% |
| Sep 30, 2021 | -77.65% |